BenzingaAugust 13, 2026 at 10:09 AM NY2 Months Ago
Barclays Maintains Overweight on Cytokinetics, Raises Price Target to $110
Barclays analyst Emily Field maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $95 to $110.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
